DSIP: The Sleep Peptide That Still Has No Receptor

The short version

DSIP — Delta Sleep-Inducing Peptide — is a naturally occurring nine-amino-acid peptide first isolated from the cerebral venous blood of rabbits during electrically induced sleep in 1977. Its INN is Emideltide. It was named for its reported ability to enhance slow-wave (delta) EEG activity when infused into the brain, and it has been studied since then for sleep promotion, stress-hormone modulation, and longevity effects in animals.

Here is the honest picture. Despite more than forty years of research, DSIP has no identified receptor, no identified gene, and no identified protein precursor. A 2006 review in the Journal of Neurochemistry — a peer-reviewed mainstream journal, not a peripheral one — described DSIP as a "still unresolved riddle" whose sleep-promotion evidence is "extremely poorly documented and still weak" ^[14]. The human trials that exist are small, old, and largely uncontrolled. A large share of people who try it report no effect at all. That is the honest starting point for reading this page.

What it is

DSIP is the linear nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code: WAGGDASGE), with molecular formula C35H48N10O15. It is endogenous — the body produces it naturally, and it appears in human cerebrospinal fluid and plasma. A naturally occurring phosphorylated form (DSIP-P) is also described in the literature and is reported as more potent in some assays. Despite being endogenous and widely found, no gene encoding DSIP, no DSIP precursor protein, and no dedicated DSIP receptor has ever been conclusively isolated ^[14]. It is not an approved drug anywhere. The name Emideltide is its INN but no Emideltide drug product has been approved or marketed by any regulator. Material sold online is research-grade with no pharmaceutical quality, purity, or sterility standard.

How it works

The short answer is: not fully known, and that is not hedging — it is the peer-reviewed scientific consensus. The 2006 Journal of Neurochemistry review explicitly stated that the sleep evidence is weakly documented, that no DSIP receptor has been isolated, and that synthetic analogs (not native DSIP) showed the clearest sleep-promoting effects ^[14]. What is known:

• DSIP crosses the blood-brain barrier via a saturable transporter that is competitively inhibited by L-tryptophan. This transporter-mediated BBB crossing is one of the better-characterized aspects of its biology.
• Its reported growth-hormone-releasing effect in rats runs through a dopaminergic relay (sensitive to pimozide blockade), but a human replication study in women found no GH or prolactin response, illustrating the cross-species inconsistency that runs through its whole record.
• Its reported ACTH-lowering effect in men (significant reduction for at least 3 hours after intravenous injection at 25 nmol/kg) was not reproduced in a later human HPA study — another example of the reproducibility problem ^[16].
• A 2024 engineering study found that a DSIP fusion peptide engineered to cross the BBB more efficiently reduced wakefulness in insomnia mice and restored monoamine levels — but the native DSIP was outperformed by the modified version, which is consistent with the review conclusion that analogs drive clearer effects ^[13].

Its dose-response is reportedly non-monotonic: higher doses are not reliably more effective than intermediate ones, which makes interpretation of any finding harder.

What the research shows

Mechanistic status — a frank summary. The foundational 2006 review concluded that DSIP's sleep evidence is extremely poorly documented, that no receptor, gene, or precursor has been identified, and that analogs outperform native DSIP — a net assessment that the compound's basic biology remains unresolved ^[14].

BBB-crossing fusion peptide in insomnia mice. In a 2024 study, a DSIP fusion peptide engineered for BBB penetration reduced daily wakefulness from approximately 720 minutes to approximately 500 minutes (a 31% reduction) in mice with PCPA-induced insomnia, restored melatonin, serotonin, and dopamine levels, produced anxiolytic and antidepressant behavioral effects, and increased hippocampal neuron density — outperforming unmodified DSIP on all these measures ^[13].

ACTH modulation in men. Intravenous DSIP at 25 nmol/kg in human men significantly reduced plasma ACTH-like immunoreactivity for at least 3 hours while cortisol was unaffected ^[16]. This is one of the handful of published human data points and speaks to neuroendocrine effects, not sleep per se.

Sleep in chronic insomniacs. An early (1981) intravenous DSIP study in six middle-aged chronic insomniacs found longer sleep duration, fewer interruptions, slightly more REM, and no daytime sedation; effects appeared in the second hour after injection, with a slight arousal in the first hour ^[17]. This remains one of the very few human sleep-outcome data points — small, old, and not replicated in modern controlled trials.

Longevity signal in mice. Monthly courses of a DSIP-containing preparation (Deltaran) in female mice increased maximum lifespan by 24.1%, extended survivor lifespan by 17.1%, reduced spontaneous tumor incidence 2.6-fold, and reduced chromosome aberrations by 22.6% ^[15]. This evidence is single-lineage, from a small set of related Russian groups, and needs independent replication before any strong claim can be made.

Reported effects, cautions & safety

The following are drawn from LongeCity forum threads, peptide community writeups, and biohacker discussion. They are anecdotal, not clinical evidence, and are kept entirely separate from the cited research findings above.

Among people who respond, the most frequently described upside is an easier transition into sleep: a quieter mind, fewer racing thoughts, and a sense of relaxation arriving within minutes. Responders commonly describe sleeping more heavily, waking less, and feeling the sleep they got was 'worth more.' A particularly consistent praise — often contrasted explicitly with melatonin — is waking without heavy grogginess. More vivid, more memorable dreams are one of the most commonly reported experiences, including from people who normally do not recall dreaming. A minority find unusually intense dreams disruptive.

The most important honest signal is the one that contradicts the name: a large share of people report that DSIP did nothing for them. One commonly cited practitioner estimate is that it works meaningfully for only about half of those who try it, and forums carry many straightforward 'didn't notice anything' reports. Unpredictable and delayed timing is reported by a notable minority — including a striking forum account of sedation arriving the next day during work hours. Next-day grogginess is reported by a minority, especially with heavier use. Headache is the most commonly reported side effect, usually mild and transient. Mild nausea, dizziness, or lightheadedness is occasionally reported.

From the cited literature, the key cautions are:

• Sold only as an unregulated research chemical. No Emideltide product has ever been approved or marketed by any regulator. Purity, identity, sterility, and dose accuracy are not independently guaranteed ^[14].
• Its mechanism is genuinely unknown, making interactions unpredictable. No receptor, gene, or precursor has been isolated. A non-monotonic dose-response has been reported. When the basic mechanism is unknown, there is no sound basis for predicting interactions with medications or medical conditions ^[14].
• Essentially no long-term human safety data. Human study is limited to small, mostly 1980s pilot trials and short neuroendocrine experiments. Long-term safety is unknown, not established ^[17].
• Combining with sedatives, sleep aids, or alcohol is untested. DSIP has been studied as an adjunct in anaesthesia and proposed to interact with the opioid system. Stacking an unknown-mechanism agent on top of other sedating substances has never been formally tested.
• Reported benefits are inconsistent and frequently absent. Both community experience and the formal literature confirm unreliable effects. A controlled human insomnia study found only modest benefit ^[17]. Approaching it with the expectation that it will reliably improve sleep is not supported by the evidence.
• Self-experimenting for sleep can mask an undiagnosed sleep disorder. Persistent sleep trouble can indicate treatable conditions such as sleep apnea, depression, or a circadian disorder. DSIP is not a substitute for evaluation.

Where it fits in cognitive research

DSIP is the most honestly uncertain compound on this desk — a naturally occurring peptide with a forty-year research history and no resolved receptor, gene, or mechanism. That puts it in an unusual position: it is neither a failed compound that showed nothing nor a well-characterized one that clearly works. Its sleep angle is distinct from Semax's cognitive-activation story and Selank's anxiety story, and the three together cover a reasonable range of the neuroactive-peptide landscape. Read alongside Semax for neuroprotection and focus, and Selank for the anxiety end of the spectrum. The comparison page lines all three up side by side.